Yukihiro Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yukihiro Yoshida has a total of 304 co-authors. Here are the top co-authors by number of shared publications:
- Shun-Ichi Watanabe
Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan
95 shared publications - Noriko Motoi
Department of Pathology Saitama Cancer Center Saitama Japan
73 shared publications - Atsushi Ochiai
Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan
71 shared publications - Kazunori Aoki
Department of Immune Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan
71 shared publications - Akiyoshi Hirayama
Institute for Advanced Biosciences, Keio University, Yamagata, Japan
70 shared publications - Hideaki Mizuno
Chugai Pharmaceutical Co., Ltd., Research Division, Yokohama, Kanagawa, Japan
70 shared publications
Latest Publications
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Multiomics Analysis of Malignant Pleural Mesothelioma Reveals the Immunological Microenvironment Associated with MTAP Loss and Immunotherapy Outcomes
Purpose: Nivolumab plus ipilimumab is a standard first-line therapy for unresectable malignant pleural mesothelioma (MPM), yet biomarkers predicting immune checkpoint inhibitor (ICI) efficacy remain undefined. We aimed to identify genomic and tumor immune microenvironmental features associated with ICI response in MPM. Experimental Design: We analyzed two independent MPM cohorts. The discovery cohort included patients at the National Cancer Center Hospital (2012â2022) with frozen tumor tissues available for whole-genome sequencing (WGS) and RNA sequencing. Genomic alterations, transcriptomic profiles, immune cell composition, and T-cell receptor repertoire were analyzed, and key findings were validated in a nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) cohort. Results: The WGS cohort comprised 52 patients. Among ICI-treated patients, overall response rates were 30% in the WGS cohort and 29.4% in the C-CAT cohort. Genomic analyses identified frequent alterations in BAP1 and NF2, across both cohorts. ICI responders showed higher T-cell receptor diversity, increased CD8âş T-cell infiltration, and enrichment of M1 macrophages compared with non-responders. MTAP loss was associated with higher CD8âş T-cell infiltration and T-cell receptor diversity, and was linked to a higher ICI response rate in the C-CAT cohort. In contrast, BAP1 and NF2 alterations showed no consistent association with immune features or ICI efficacy. Conclusions: An immune-active tumor microenvironment characterized by high T-cell receptor diversity, CD8âş T-cell infiltration, and M1 macrophage enrichment was associated with favorable ICI responses in MPM. MTAP loss was linked to immune-related features and a higher ICI response, supporting further investigation of MTAP loss as a candidate biomarker.
- 6 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Multiomics Analysis of Malignant Pleural Mesothelioma Reveals the Immunological Microenvironment Associated with MTAP Loss and Immunotherapy Outcomes
Purpose: Nivolumab plus ipilimumab is a standard first-line therapy for unresectable malignant pleural mesothelioma (MPM), yet biomarkers predicting immune checkpoint inhibitor (ICI) efficacy remain undefined. We aimed to identify genomic and tumor immune microenvironmental features associated with ICI response in MPM. Experimental Design: We analyzed two independent MPM cohorts. The discovery cohort included patients at the National Cancer Center Hospital (2012â2022) with frozen tumor tissues available for whole-genome sequencing (WGS) and RNA sequencing. Genomic alterations, transcriptomic profiles, immune cell composition, and T-cell receptor repertoire were analyzed, and key findings were validated in a nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) cohort. Results: The WGS cohort comprised 52 patients. Among ICI-treated patients, overall response rates were 30% in the WGS cohort and 29.4% in the C-CAT cohort. Genomic analyses identified frequent alterations in BAP1 and NF2, across both cohorts. ICI responders showed higher T-cell receptor diversity, increased CD8âş T-cell infiltration, and enrichment of M1 macrophages compared with non-responders. MTAP loss was associated with higher CD8âş T-cell infiltration and T-cell receptor diversity, and was linked to a higher ICI response rate in the C-CAT cohort. In contrast, BAP1 and NF2 alterations showed no consistent association with immune features or ICI efficacy. Conclusions: An immune-active tumor microenvironment characterized by high T-cell receptor diversity, CD8âş T-cell infiltration, and M1 macrophage enrichment was associated with favorable ICI responses in MPM. MTAP loss was linked to immune-related features and a higher ICI response, supporting further investigation of MTAP loss as a candidate biomarker.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S1. Study One-hundred sixty eight genes which were differently expressed between these two groups were further narrowed down by NMF analysis. For the details of genes included in R1/R2/R3 and N1/N2/N3, please see Supplementary Table S1.
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S1. Study One-hundred sixty eight genes which were differently expressed between these two groups were further narrowed down by NMF analysis. For the details of genes included in R1/R2/R3 and N1/N2/N3, please see Supplementary Table S1.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
The study concept and the identification of candidate genes. A, The analytic flow of this study including cohort 1 (a discovery set of matched patients who experienced disease recurrence and patients who did not for >5 years), cohort 2a (a testing set of a real-world cohort), cohort 2b (additional real-world cohort), and TCGA database (a validation set). B, OPLS-DA analysis revealed that gene expression status differed between patients who experienced disease recurrence (red) and those who did not for >5 years (blue). C, A volcano plot to identify differentially expressed genes between patients who experienced disease recurrence and those who did not for >5 years. Of the genes that meet the selection criteria, upregulated or downregulated genes in the recurrence group are shown in red or blue, respectively. Fc, fold change.
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
The study concept and the identification of candidate genes. A, The analytic flow of this study including cohort 1 (a discovery set of matched patients who experienced disease recurrence and patients who did not for >5 years), cohort 2a (a testing set of a real-world cohort), cohort 2b (additional real-world cohort), and TCGA database (a validation set). B, OPLS-DA analysis revealed that gene expression status differed between patients who experienced disease recurrence (red) and those who did not for >5 years (blue). C, A volcano plot to identify differentially expressed genes between patients who experienced disease recurrence and those who did not for >5 years. Of the genes that meet the selection criteria, upregulated or downregulated genes in the recurrence group are shown in red or blue, respectively. Fc, fold change.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S9. Prognostic implications of BMP6 and OLFM1 (stage-specific analysis).
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S9. Prognostic implications of BMP6 and OLFM1 (stage-specific analysis).
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Recurrence-free survival of patients in Cohort 2a in the high expression group and low expression group for each gene (A, BMP6; B, KCNK3; C, NFASC; D, OLFM1; E, PEG3; and F, TNXB).
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Recurrence-free survival of patients in Cohort 2a in the high expression group and low expression group for each gene (A, BMP6; B, KCNK3; C, NFASC; D, OLFM1; E, PEG3; and F, TNXB).
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S7. Concordance rates (A) between identified 6 genes and p-values (B).
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S7. Concordance rates (A) between identified 6 genes and p-values (B).
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
RFS of patients categorized by BMP6 and OLFM1 expression status. A and B, RFS in cohort 2a, a real-world cohort of patients with pStage I nonsquamous NSCLC whose tumors were analyzed using PolyA sequencing. C and D, RFS in the cohort of patients with EGFR mutations extracted from cohort 1 and cohort 2. H&H, high and high indicates higher expression of both BMP6 and OLFM1; H&L, high and low indicates higher expression for either of the BMP6 and OLFM1 and lower expression for the other; L&L, low and low indicates lower expression of both BMP6 and OLFM1.
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
RFS of patients categorized by BMP6 and OLFM1 expression status. A and B, RFS in cohort 2a, a real-world cohort of patients with pStage I nonsquamous NSCLC whose tumors were analyzed using PolyA sequencing. C and D, RFS in the cohort of patients with EGFR mutations extracted from cohort 1 and cohort 2. H&H, high and high indicates higher expression of both BMP6 and OLFM1; H&L, high and low indicates higher expression for either of the BMP6 and OLFM1 and lower expression for the other; L&L, low and low indicates lower expression of both BMP6 and OLFM1.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Table S4. Multivariable analysis of 6 genes for RFS in the Cohort 2a (N = 125)
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Table S4. Multivariable analysis of 6 genes for RFS in the Cohort 2a (N = 125)
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Table S2. The list of differently expressed genes in Cohort 1
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Table S2. The list of differently expressed genes in Cohort 1
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S3. Mutational signature analysis in Recurrence group (A) and in Control group (B).
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S3. Mutational signature analysis in Recurrence group (A) and in Control group (B).